Chronic Myeloid Leukemia as Secondary Malignancy Following the Treatment of Hodgkin Lymphoma: A Case Series

Secondary malignancies are relatively common and clinically important phenomena following both chemotherapy and radiotherapy. The majority of these cases are acute leukemias, the occurrence of which have been thoroughly documented and studied. More rarely, chronic myeloid leukemias (CML) may arise s...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2019-08, Vol.39 (8), p.4333-4335
Main Authors: Millett, Ralph, Aggarwal, Anita, Tabbara, Imad, Nassereddine, Samah
Format: Article
Language:English
Subjects:
Chemotherapy
Chronic myeloid leukemia
Hodgkin's lymphoma
Janus kinase 2
Leukemia
Literature reviews
Lymphoma
Malignancy
Mutation
Myeloid leukemia
Radiation therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Secondary malignancies are relatively common and clinically important phenomena following both chemotherapy and radiotherapy. The majority of these cases are acute leukemias, the occurrence of which have been thoroughly documented and studied. More rarely, chronic myeloid leukemias (CML) may arise subsequent to treatment of a primary malignancy. Literature review on such developments following treatment of Hodgkin's Lymphoma (HL) is scant. Herein, the authors present three cases of CML diagnosed within five years of treatment initiation for Hodgkin's Lymphoma (HL); one of the three patients had CML with atypical variant carrying a rare mutation with BCR-JAK2 fusion.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.13600